Rigel Pharmaceuticals | RIGL - Current Assets

Stock Price
30.29
Daily Change
-0.43 -1.40%
Monthly
15.21%
Yearly
57.11%
Q2 Forecast
29.64

Rigel Pharmaceuticals reported $214.93M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Agenus USD 133.44M 514K Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Anika Therapeutics USD 103.36M 1.77M Dec/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Celldex Therapeutics USD 534.66M 69.68M Dec/2025
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Heron Therapeutics USD 238.07M 8.67M Dec/2025
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Ligand Pharmaceuticals USD 832.27M 78.35M Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Veracyte USD 488.38M 39.15M Dec/2025